Přístupnostní navigace
E-application
Search Search Close
Publication detail
DOSTÁLOVÁ, S. POLANSKÁ, H. SVOBODOVÁ, M. BALVAN, J. KRYŠTOFOVÁ, O. MASAŘÍK, M. ECKSCHLAGER, T. STIBOROVÁ, M. HEGER, Z. ADAM, V.
Original Title
In vivo biocompatibility of site-directed apoferritin-based nanocarrier for cardiotoxic antitumour drug doxorubicin
Type
conference paper
Language
English
Original Abstract
Doxorubicin (DOX), a potent anthracycline antibiotic [1], is used in conventional cancer therapy for the treatment of various solid and haematological malignancies, such as breast [2], lung [3], bladder [4] or Hodgkin lymphoma [5]. However, up to 26% of patients treated with DOX develop arrhythmia or cardiomyopathy [6]. Co-administration with cardioprotective drugs can lead to other unwanted side effects, such as the development of secondary malignancies in case of dexrazoxane [7]. This effectively limits DOX dose that can be administered to the patients [6].
Keywords
Doxorubicin (DOX); cancer cells; nanocarrier
Authors
DOSTÁLOVÁ, S.; POLANSKÁ, H.; SVOBODOVÁ, M.; BALVAN, J.; KRYŠTOFOVÁ, O.; MASAŘÍK, M.; ECKSCHLAGER, T.; STIBOROVÁ, M.; HEGER, Z.; ADAM, V.
Released
10. 5. 2017
ISBN
2296-9667
Periodical
European & Global Summit for Clinical Nanomedicine and Targeted Medicine
State
Swiss Confederation
Pages from
168
Pages to
169
Pages count
2
BibTex
@inproceedings{BUT141783, author="Simona {Dostálová} and Hana {Polanská} and Markéta {Svobodová} and Jan {Balvan} and Olga {Kryštofová} and Michal {Masařík} and Tomáš {Eckschlager} and Marie {Stiborová} and Zbyněk {Heger} and Vojtěch {Adam}", title="In vivo biocompatibility of site-directed apoferritin-based nanocarrier for cardiotoxic antitumour drug doxorubicin", booktitle="10th European and Global Summit for Clinical Nanomedicine and Targeted Medicine: witnessing the solutions and tackling the hurdles", year="2017", journal="European & Global Summit for Clinical Nanomedicine and Targeted Medicine", pages="168--169", issn="2296-9667" }